{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:59:00Z","timestamp":1790362740507,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejca.2025.115447","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:19:01Z","timestamp":1746058741000},"page":"115447","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-8455","authenticated-orcid":false,"given":"Chris","family":"Labaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-5695","authenticated-orcid":false,"given":"Marc","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Bakouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Hobeika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razane El Hajj","family":"Chehade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Chebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2512-6131","authenticated-orcid":false,"given":"Stergios","family":"Boussios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Anthony Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Pavlidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-0991","authenticated-orcid":false,"given":"Elie","family":"Rassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115447_bib1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41571-020-0359-1","article-title":"Progress in refining the clinical management of cancer of unknown primary in the molecular era","volume":"17","author":"Rassy","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib2","doi-asserted-by":"crossref","DOI":"10.1200\/OA-24-00041","article-title":"Cancer of unknown primary site: a new era of practice-changing approaches to diagnosis, staging, and precision therapy","author":"Greco","year":"2024","journal-title":"JCO Oncol Adv"},{"key":"10.1016\/j.ejca.2025.115447_bib3","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib4","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(11)61178-1","article-title":"Cancer of unknown primary site","volume":"379","author":"Pavlidis","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115447_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ctrv.2018.04.011","article-title":"The current evidence for a biomarker-based approach in cancer of unknown primary","volume":"67","author":"El Rassy","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115447_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102204","article-title":"Redefining cancer of unknown primary: is precision medicine really shifting the paradigm?","volume":"97","author":"Olivier","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115447_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102407","article-title":"Systematic review of the CUP trials characteristics and perspectives for next-generation studies","volume":"107","author":"Rassy","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ejca.2025.115447_bib8","doi-asserted-by":"crossref","first-page":"v851","DOI":"10.1093\/annonc\/mdz394","article-title":"A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)","volume":"30","author":"Fizazi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.18.00771","article-title":"Randomized phase II trial comparing site-specific treatment based on gene expression profiling with carboplatin and paclitaxel for patients with cancer of unknown primary site","volume":"37","author":"Hayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib10","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S1470-2045(24)00344-9","article-title":"Molecular diagnosis and site-specific therapy in cancer of unknown primary: an important milestone","volume":"25","author":"Greco","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0140-6736(24)00975-9","article-title":"Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management","volume":"404","author":"Rassy","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115447_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study","volume":"404","author":"Kr\u00e4mer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115447_bib13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejca.2025.115447_bib15","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(16)30297-2","article-title":"Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis","volume":"17","author":"Moran","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2019.12.016","article-title":"The role of site-specific therapy for cancers of unknown of primary: a meta-analysis","volume":"127","author":"Rassy","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115447_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100407","article-title":"Site-specific therapy in cancers of unknown primary site: a systematic review and meta-analysis","volume":"7","author":"Ding","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.115447_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","article-title":"EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib","volume":"2","author":"Corcoran","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2025.115447_bib20","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115447_bib21","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115447_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejca.2014.10.009","article-title":"Multicentre randomised phase II trial of gemcitabine +\u2009platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2","volume":"51","author":"Oudard","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115447_bib23","first-page":"1","article-title":"New clinical trials in CUP and a novel paradigm in cancer classification","volume":"2024","author":"Rassy","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115447_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/oncolo\/oyad248","article-title":"Can precision oncology benefit patients with cancers of unknown primary?","volume":"28","author":"Rassy","year":"2023","journal-title":"Oncologist"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500228X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095980492500228X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T07:58:29Z","timestamp":1749801509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095980492500228X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":24,"alternative-id":["S095980492500228X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115447","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecularly directed therapy in cancers of unknown primary: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115447","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115447"}}